Genfit SA · EURONEXT:GNFT
Genfit SA — Investor Presentation (March 2019)
36 slides from Genfit SA's investor presentation, March 2019
Slide 1: March 2019 Corporate Presentation
MARCH2019 CORPORATE PRESENTATION March 2019 I. CORPORATE HIGHLIGHTS II. LEADERSHIP IN NASH & PBC 1
Slide 2: Disclaimer
Disclaimer Important Information and Forward Looking Statements IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING •THIS PRESENTATION HAS BEEN PREPARED BY GENFIT AND IS FOR INFORMATION PURPOSES ONLY. •CERTAIN OF THE INFORMATION CONTAINED HEREIN CONCERNING ECONOMIC TRENDS AND PERFORMANC
Slide 3: I. Corporate Highlights
I. CORPORATE , HIGHLIGHTS |
Slide 4: Company Profile
Company Profile BACKGROUND • Public company focused on metabolic diseases and associated complications, including liver related disorders • World-leading expert in nuclear receptor based drug discovery • Lead drug candidate discovered in-house • Founded in 1999 (Lille, Paris, France – Cambridge, Uni
Slide 5: Experienced Management Team and Highly Respected Advisory Board
Experienced Management Team and Highly Respected Advisory Board • Jean-François Mouney, Chief Executive Officer, co-founded the company in 1999 • The executive team and board of directors have a deep experience at leading biotech companies, large pharmaceutical companies and academic institutions •
Slide 6: A Comprehensive Strategy in Liver and Metabolic Healthcare
A Comprehensive Strategy in Liver and Metabolic Healthcare 1. TREATMENT 2. DIAGNOSIS Identifying Providing PATIENTS ELIGIBLE FOR TREATMENTS THERAPEUTIC SOLUTIONS 4. LAUNCH EXCELLENCE Preparing for COMMERCIALIZATION 3. AWARENESS Optimizing STANDARD of CARE 6
Slide 7: Robust Pipeline Focused on Liver and Metabolic Diseases With Near-Term Clinical Milestones
Robust Pipeline Focused on Liver and Metabolic Diseases With Near-Term Clinical Milestones • Currently finalizing analytical and clinical study designs • License agreement with LabCorp – January 2019 • 2018: alignment with FDA on path forward to validate NIS4 • LDT anticipated release in 2019 • Disc
Slide 8: Upcoming Expected Catalysts
Upcoming Expected Catalysts PBC (elafibranor) NASH (elafibranor) PHASE 2 – DATA READOUT PHASE 3 – INTERIM DATA READOUT for ACCELERATED MARKET APPROVAL 2018 2019 2020 PBC (elafibranor) PHASE 3 – LAUNCH NASH Pediatric (elafibranor) PHASE 2 – 1st PATIENT NASH Diagnostic (biomarkers) NASH Diagno
Slide 9: II. Leadership in NASH and PBC
II. LEADERSHIP IN NASH AND PBC 9
Slide 10: A Potential to Become a Leader in NASH and PBC
A Potential to Become a Leader in NASH and PBC 1. TREATMENT NASH & FIBROSIS Elafibranor Combinations Nitazoxanide PBC Elafibranor 10
Slide 11: NASH, a Disease Leading to Cirrhosis and HCC, Represents a Large and Untapped Market
NASH, a Disease Leading to Cirrhosis and HCC, Represents a Large and Untapped Market › Leading cause of liver disease in developed countries; ~20 million in the United States suffer from NASH and advanced fibrosis › Cardiovascular events are the leading cause of death in NASH › Multifaceted disease
Slide 12: Elafibranor, First-in-class, has Pluripotent Activities
Elafibranor, First-in-class, Elafibranor, First-in-class, has has Pluripotent Pluripotent Activities: Activities PPARα/δ Regulate PPARα and Multiple δ Regulate Pathways Multiple Pathways Essential Essential inin NASH NASH 12
Slide 13: Elafibranor Is One of the Most Advanced NASH Product Candidates
Elafibranor Is One of the Most Advanced NASH Product Candidates 2018 2019 2020 2021 PHASE 3 interim Potential NDA FIRST wave candidates DATA READOUT Submission • Elafibranor (Genfit) • Ocaliva (Intercept) • Selonsertib (Gilead) • Cenicriviroc (Allergan) PHASE 2 SECOND wave candidates DATA READOUT •
Slide 14: Evidence from Phase 2 NASH Trials
Evidence from Phase 2 NASH Trials Elafibranor is the only product candidate from the first wave in NASH to have demonstrated all four of (i) EFFICACY ON "NASH RESOLUTION WITHOUT WORSENING OF FIBROSIS" (ii) IMPROVEMENT OF LIPID PROFILE (iii) IMPROVEMENT OF METABOLIC PROFILE (iv) TOLERABILITY TOP LINE
Slide 15: Elafibranor in NASH: Phase 2b GOLDEN-505 Results
Elafibranor Elafibranor in2b Phase NASH Results: A Solid Ground for RESOLVE-IT GOLDEN-505 Phase 3 trial Phase 2 Results* › Data published in peer-review journal › Elafibranor resolved NASH without worsening of fibrosis, which has been recommended as primary endpoint for Phase 3 pivotal trials in NAS
Slide 16: Elafibranor Phase 2b Results: Additional Key Benefits for NASH Patients
Elafibranor Elafibranor Phasein2b NASH Results: Additional Key Benefits GOLDEN-505 Phasefor NASH Patients 2 Results* Beneficial effect on Favorable Beneficial effect on - Glucose Homeostasis - Safety profile Lipid Markers - Insulin Sensitivity - Tolerability profile in NASH patients in T2D NASH Pati
Slide 17: Elafibranor Phase 3 Design: Details and Timing
Elafibranor Phase 3 Design: Details and Timing > 250 centers ~ 1000 ~ 2000 (worldwide) patients patients ACCELERATED MARKET AUTHORIZATION • SUBPART H (FDA) • CONDITIONAL APPROVAL (EMA) FIRST TREATMENT PERIOD 18 MONTHS EXTENSION PERIOD Placebo Placebo Elafibranor 120mg Elafibranor 120mg 2:1 2:1 TRIAL
Slide 18: Clinical Requirements for Future Combinations: Elafibranor as Backbone Therapy
Clinical Requirements for Future Combinations: Elafibranor Shows Potential as Backbone Therapy ANTI-NASH PURE ANTI-FIBROTIC drug candidates drug candidates 1 Addressing NASH (the underlying cause) 2 Addressing FIBROSIS (the consequence) Among product candidates in Phase 3, only ELAFIBRANOR and OCALI
Slide 19: Proactive Evaluation of Potential Add-on Drug Candidates for Elafibranor in NASH
Proactive Evaluation of Potential "Add-on" Drug Candidates for Elafibranor in NASH BACKBONE Add-On ELAFIBRANOR DRUG X ELAFIBRANOR + NTZ ELAFIBRANOR + FXR ELAFIBRANOR + ACC ELAFIBRANOR + ANTI-T2D 19
Slide 20: Nitazoxanide (NTZ): GENFIT's Pure Anti-Fibrotic Drug Candidate
Nitazoxanide (NTZ): GENFIT’s Pure Anti-Fibrotic Drug Candidate Nitazoxanide (NTZ) › A new anti-fibrotic drug candidate, part of GNFT’s discovery program › Currently approved as an anti-parasitic › Early pre-clinical studies have shown promising anti-fibrotic activity 3 › A wholly owned IP position i
Slide 21: Nitazoxanide (NTZ): Investigator-initiated Phase 2a
Nitazoxanide (NTZ): Investigator-initiated Phase 2a OBJECTIVE Evaluate the safety and efficacy of NTZ NASH patients with fibrosis Stage 2 (significant fibrosis) or 3 (severe fibrosis) Non-invasive readout related to fibrosis to assess the changes from baseline to the end of treatment: de novo c
Slide 22: PBC: Elafibranor Well Positioned to Address Unmet Needs
PBC (Primary Biliary Cholangitis): Elafibranor Well Positioned to Address Unmet Needs in this Severe Chronic Liver Condition HIGH UNMET NEEDS RATIONALE for ELAFIBRANOR • Cholestatic chronic autoimmune disease • Affecting intrahepatic bile ducts • Severe liver disease • Prevalence in the general popu
Slide 23: Phase 2a Study with Elafibranor in PBC
Phase 2a Study with Elafibranor in PBC (Primary Biliary Cholangitis) 1st Patient enrolled May 2017 12-WEEK ANALYSIS TREATMENT PERIOD 12 WEEKS UDCA + Placebo UDCA + Elafibranor 80mg 2:1 UDCA + Elafibranor 120mg Study population Primary endpoint adult patients with PBC effect of daily oral and inadequ
Slide 24: Positive Data Readout in PBC: Key Takeaways
Elafibranor Elafibranor in NASH Phase 2 Results: Positive Data ReadoutPhase GOLDEN-505 in PBC – Key Takeaways 2 Results* › Elafibranor successfully meets PRIMARY ENDPOINT (“change at week 12 in serum alkaline phosphatase (ALP) from baseline”) with: › High statistical significance (p<0.001) › Substan
Slide 25: Highly Competitive Profile in PBC
Elafibranor Elafibranor in NASH Phase 2 Results: AGOLDEN-505 Highly Competitive Profile Phase 2 Results* TOP LINE COMPARISON EFFICACY in PHASE 2 (12-week data) Elafibranor1 Ocaliva2 Seladelpar3 (GENFIT) (INTERCEPT) (CYMABAY) 80mg 120mg pbo 10mg pbo 5mg 10mg pbo ALP -48% -41% +3% -24% +3% -33% -45% N
Slide 26: Positive Data Readout in PBC: Additional Key Benefits
Elafibranor Elafibranor in NASH Phase 2 Results: Positive Data Readout GOLDEN-505in PBC – Additional Phase 2 Results* Key Benefits Improvements in: Beneficial effect: Favorable: Markers of PBC › Early indication of › Safety profile › Gamma-glutamyl improvement in › Tolerability profile transferases
Slide 27: 2. Diagnosis: A Pioneering & Proactive Approach to Unlock the NASH Market
A Pioneering & Proactive Approach to Unlock the NASH Market 2. DIAGNOSIS Towards a large scale industrial solution 27
Slide 28: NASH Diagnosis: A Need for Simple Blood-based Solutions
NASH Diagnosis: A Need for Simple Blood-based Solutions Current bottleneck BIOPSY Imperfect "Gold Standard" IMAGING TECHNIQUES Non-invasive, but limited Ideal situation “…there is an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessm
Slide 29: GENFIT's Approach Designed to Ensure the NASH Market Can Reach its Full Potential
GENFIT’s Approach Designed to Ensure the NASH Market Can Reach its Full Potential Focus on a specific and relevant clinical question: HEALTHY NAFLD CIRRHOSIS NO NASH NASH N/A TO BE TREATED Steatosis ≥1 NAS ≥ 4 Ballooning ≥1 F2 or higher Inflammation ≥1 LDT anticipated release in 2019 Regulatory subm
Slide 30: NIS4 Commercialization: Planned Strategy and Objectives
NIS4 Commercialization: Planned Strategy and Objectives 2019 2020 2021 PARTNERSHIP U.S. Commercial Licensing Agreement • LDT for Clinical Research E.U. Commercial • Expansive Research Licensing Agreement REGULATORY Prepare IVD for FDA Submission • IVD Approval 30
Slide 31: The Future Patient Journey with IVD Test
The Future Patient Journey with IVD Test, for Better Clinical Management of NASH Patients 31
Slide 32: 3. Awareness
A Pioneering & Proactive Approach to Unlock the NASH Market 3. AWARENESS 32
Slide 33: The NASH Education Program
The NASH Education ProgramTM For BETTER CARE NASH PHYSICIANS PATIENTS (Non-Alcoholic Incl. DIABETOLOGISTS, Individuals at risk, ENDOCRONOLOGISTS, Families SteatoHepatitis) CARDIOLOGISTS, GPs 1 Serious liver condition Sub-Optimal 2 PATIENT CARE Unprecedented rise in prevalence 3 Silent, by nature Yet
Slide 34: Success for the Inaugural International NASH Day
A Worldwide Success for the Inaugural Edition of International NASH Day, in 25+ Countries ROADMAP 2019 A large coalition of 20+ stakeholders, across the United States, Europe, and LATAM, including: • Patient associations • Learned societies New and larger • Companies leadership Focus on education 34
Slide 35: A Relevant Approach to Market Access to Prepare for Commercialization
A Relevant Approach to Market Access to Prepare for Commercialization 1. TREATMENT 2. DIAGNOSIS Ideal drug profile Market Enabler 1st line treatment monotherapy (patient identification) Cornerstone combination therapies 4. LAUNCH EXCELLENCE 3. AWARENESS Market Enabler (physicians’ knowledge
Slide 36: A Strategy to Maximize Sales Uptake and Transform the Company
A Strategy to Maximize Sales Uptake and Transform the Company Elafibranor: uniquely positioned in the first wave of NASH products Objective: transform GENFIT into a biopharma, with a mixed revenue stream from: Direct sales of elafibranor Royalties from potential licensing deal World class